Approval belongs
to the exact product.
Resolve the brand, active ingredient, application number, presentation, labeled use, and current primary record before comparing any claim. Similar names do not make research vials, compounded drugs, and approved medicines equivalent.
These pages summarize current FDA and DailyMed records for navigation and comparison. They contain no affiliate links, seller rankings, dosing instructions, or individual treatment advice.
Records checked through July 20, 2026Start with the brand. Verify the record.
Every card opens a substantive profile with the approved-use boundary, product identity, name collisions, direct answers, and two primary-source records.
WEGOVY
WEGOVY is an FDA-approved semaglutide prescription product with a product-specific label. That approval does not transfer to every item advertised with the ingredient name semaglutide.
- Molecular class
- FDA-approved incretin medicine
- Dosage form
- Injection and tablets
- Route
- Subcutaneous and oral
- Approval record
- WEGOVY NDA first approved in 2021
- Current label
- June 18, 2026
ZEPBOUND
ZEPBOUND is an FDA-approved tirzepatide prescription product for defined uses. The ingredient also appears in other product and online-sales contexts that belong to different regulatory records.
- Molecular class
- FDA-approved incretin medicine
- Dosage form
- Injection
- Route
- Subcutaneous
- Approval record
- ZEPBOUND NDA first approved in 2023
- Current label
- April 22, 2026
SAXENDA
SAXENDA is an FDA-approved liraglutide prescription product with a weight-management label for defined adult and pediatric populations. It is not a generic approval umbrella for every liraglutide product.
- Molecular class
- FDA-approved incretin medicine
- Dosage form
- Injection
- Route
- Subcutaneous
- Approval record
- SAXENDA NDA first approved in 2014
- Current label
- June 2026
VYLEESI
VYLEESI is the FDA-approved bremelanotide prescription product. PT-141 is a name associated with the same active ingredient, but online research vials are not the approved product, presentation, or supply route.
- Molecular class
- FDA-approved melanocortin medicine
- Dosage form
- Injection
- Route
- Subcutaneous
- Approval record
- VYLEESI NDA approved June 21, 2019
- Current label
- March 2024
SCENESSE
SCENESSE is an FDA-approved afamelanotide implant for a narrowly defined EPP use. Seller-labelled Melanotan I research vials are not this implant and do not share its approval.
- Molecular class
- FDA-approved melanocortin medicine
- Dosage form
- Implant
- Route
- Subcutaneous
- Approval record
- SCENESSE NDA approved October 8, 2019
- Current label
- May 2026
EGRIFTA WR
EGRIFTA WR is an FDA-approved tesamorelin prescription product for one defined HIV-lipodystrophy use. Its label explicitly says it is not indicated for weight-loss management.
- Molecular class
- FDA-approved GHRF-analog medicine
- Dosage form
- Lyophilized powder kit
- Route
- Subcutaneous
- Approval record
- Tesamorelin BLA first approved in 2010
- Current label
- March 2025
FOUNDAYO
FOUNDAYO is the FDA-approved US product containing orforglipron, an oral small-molecule GLP-1 receptor agonist. It acts at a receptor named for a peptide hormone, but orforglipron itself is not a peptide.
- Molecular class
- FDA-approved non-peptide GLP-1 comparator
- Dosage form
- Film-coated tablets
- Route
- Oral
- Approval record
- FOUNDAYO NDA approved April 1, 2026
- Current label
- April 2026
One peptide name can lead to three different questions.
A label summary is a map to the source - not a substitute for it.
Peptide Local states the indication at a high level, then links to the current labeling in use. Warnings, contraindications, adverse reactions, instructions, and complete eligibility belong in the full prescribing information.
For decisions about a specific medicine, use the current label and speak with a licensed clinician or pharmacist. For suspected counterfeit, contaminated, or illegally marketed products, start with the safety center.
Audit the source registry →Open the peptide safety center →